Phreesia (NYSE:PHR) Upgraded at Zacks Research

Zacks Research upgraded shares of Phreesia (NYSE:PHR) from a hold rating to a strong-buy rating in a report issued on Monday,Zacks.com reports.

A number of other equities analysts have also commented on PHR. Barclays initiated coverage on shares of Phreesia in a report on Monday. They issued an “overweight” rating and a $26.00 price objective on the stock. JPMorgan Chase & Co. dropped their target price on Phreesia from $32.00 to $29.00 and set an “overweight” rating on the stock in a research report on Tuesday. BMO Capital Markets started coverage on Phreesia in a research note on Thursday, November 13th. They issued an “outperform” rating and a $32.00 price target on the stock. Weiss Ratings restated a “sell (e+)” rating on shares of Phreesia in a research note on Friday, October 31st. Finally, Stephens restated an “overweight” rating and set a $32.00 price objective on shares of Phreesia in a report on Wednesday, September 3rd. One research analyst has rated the stock with a Strong Buy rating, sixteen have given a Buy rating and one has issued a Sell rating to the company’s stock. According to data from MarketBeat, Phreesia currently has an average rating of “Moderate Buy” and an average target price of $31.13.

Phreesia Stock Up 2.5%

Shares of NYSE:PHR opened at $15.82 on Monday. The company has a market capitalization of $947.48 million, a price-to-earnings ratio of -158.13 and a beta of 0.64. The company has a 50 day moving average of $21.73 and a two-hundred day moving average of $25.12. Phreesia has a 52-week low of $15.41 and a 52-week high of $32.76. The company has a quick ratio of 2.12, a current ratio of 2.12 and a debt-to-equity ratio of 0.02.

Phreesia (NYSE:PHR) last posted its earnings results on Monday, December 8th. The company reported $0.10 EPS for the quarter, topping analysts’ consensus estimates of ($0.01) by $0.11. The business had revenue of $120.33 million for the quarter, compared to analysts’ expectations of $119.98 million. Phreesia had a negative net margin of 1.16% and a negative return on equity of 1.36%. The business’s revenue for the quarter was up 12.7% compared to the same quarter last year. During the same period in the previous year, the company posted ($0.25) earnings per share. As a group, analysts forecast that Phreesia will post -1.1 earnings per share for the current fiscal year.

Insiders Place Their Bets

In related news, insider David Linetsky sold 2,165 shares of Phreesia stock in a transaction dated Tuesday, September 16th. The stock was sold at an average price of $23.28, for a total value of $50,401.20. Following the completion of the transaction, the insider directly owned 174,952 shares in the company, valued at approximately $4,072,882.56. This trade represents a 1.22% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Also, CFO Balaji Gandhi sold 4,183 shares of the business’s stock in a transaction dated Tuesday, September 16th. The shares were sold at an average price of $23.28, for a total value of $97,380.24. Following the completion of the sale, the chief financial officer directly owned 99,125 shares of the company’s stock, valued at approximately $2,307,630. This represents a 4.05% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. In the last ninety days, insiders sold 26,174 shares of company stock valued at $603,835. 5.50% of the stock is owned by company insiders.

Institutional Investors Weigh In On Phreesia

Several institutional investors and hedge funds have recently made changes to their positions in the company. Cubist Systematic Strategies LLC bought a new position in Phreesia during the first quarter worth $774,000. Farther Finance Advisors LLC increased its stake in Phreesia by 9,375.0% during the second quarter. Farther Finance Advisors LLC now owns 3,032 shares of the company’s stock valued at $86,000 after purchasing an additional 3,000 shares during the last quarter. Arcadia Investment Management Corp MI raised its holdings in shares of Phreesia by 22.3% during the second quarter. Arcadia Investment Management Corp MI now owns 113,470 shares of the company’s stock worth $3,229,000 after purchasing an additional 20,700 shares during the period. Acadian Asset Management LLC lifted its position in shares of Phreesia by 61.6% in the 2nd quarter. Acadian Asset Management LLC now owns 364,194 shares of the company’s stock worth $10,357,000 after buying an additional 138,877 shares during the last quarter. Finally, Deutsche Bank AG boosted its holdings in shares of Phreesia by 30.6% in the 1st quarter. Deutsche Bank AG now owns 74,857 shares of the company’s stock valued at $1,913,000 after buying an additional 17,560 shares during the period. 92.10% of the stock is owned by institutional investors and hedge funds.

Phreesia Company Profile

Phreesia, Inc provides an integrated SaaS-based software and payment platform for the healthcare industry in the United States and Canada. The company offers access solutions that offers appointment scheduling system for online appointments, reminders, and referral tracking management; registration solution to automate patient self-registration; revenue cycle solution, which offer insurance-verification processes, point-of-sale payments applications, post-visit payment collection, and flexible payment options; and network connect solution to deliver clinically relevant content to patients.